dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-20 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
In it, he illustrated and described the shark under the name Canis carcharias based on the ragged nature of its teeth and its perceived similarities with dogs. Guillaume Rondelet would give it the name Lamia—after the child-eating monster from Greek Mythology—in his 1554 book Libri de Piscibus Marinis. The book identified it as the fish that swallowed the prophet Jonah in biblical texts.
One of the earliest patents for a "chain sawing machine" comprising a chain of links carrying saw teeth was granted to Frederick L. Magaw of Flatlands, New York, in 1883, apparently for the purpose of producing boards by stretching the chain between grooved drums. A later patent incorporating a guide frame was granted to Samuel J. Bens of San Francisco on January 17, 1905, his intent being to fell giant redwoods. The first portable chainsaw was developed and patented in 1918 by Canadian millwright James Shand. After he allowed his rights to lapse in 1930, his invention was further developed by what became the German company Festo in 1933. The company, now operating as Festool, produces portable power tools. Other important contributors to the modern chainsaw are Joseph Buford Cox and Andreas Stihl; the latter patented and developed an electric chainsaw for use on log bucking sites in 1926 and a gasoline-powered chainsaw in 1929, and founded a company to mass-produce them. In 1927, Emil Lerp, the founder of Dolmar, developed the world's first gasoline-powered chainsaw and mass-produced them. World War II interrupted the supply of German chainsaws to North America, so new manufacturers sprang up, including Industrial Engineering Ltd (IEL) in 1939, the forerunner of Pioneer Saws Ltd and part of Outboard Marine Corporation, the oldest manufacturer of chainsaws in North America. The first one-man chainsaw was introduced in 1950, though it was relatively heavy.
Major royal jelly proteins (MRJPs) are a family of proteins secreted by honey bees. The family consists of nine proteins, of which MRJP1 (also called royalactin), MRJP2, MRJP3, MRJP4, and MRJP5 are present in the royal jelly secreted by worker bees. MRJP1 is the most abundant, and largest in size. The five proteins constitute 83–90% of the total proteins in royal jelly. They are synthesised by a family of nine genes (mrjp genes), which are in turn members of the yellow family of genes such as in the fruitfly (Drosophila) and bacteria. They are involved in differential development of queen larvae and worker larvae, thus establishing division of labour in the bee colony.
=== Food constituents === Resistant starch from high-amylose corn, amylomaize, has been shown to reduce insulin resistance in healthy individuals, in individuals with insulin resistance, and in individuals with type 2 diabetes. Some types of polyunsaturated fatty acids (omega-3) may moderate the progression of insulin resistance into type 2 diabetes, however, omega-3 fatty acids appear to have limited ability to reverse insulin resistance, and they cease to be efficacious once type 2 diabetes is established.
Sources: en.wikipedia.org
10 mm (0.4 in) – it has well-defined gill arches and has a thin ventral finfold 21 mm (0.8 in) – dorsal and pelvic fin buds appear 33 mm (1.3 in) – embryo has protruding eyes and well-developed gill filaments 43 mm (1.7 in) – it has lost its translucency and develops slits in the egg case, allowing fluid exchange from surrounding seawater and the interior 58 mm (2.3 in) – the finfold starts to decay 66 mm (2.6 in) – the finfold and gill filaments are reduced or absent 74 mm (2.9 in) – external appearance is complete but yolk sac is still being absorbed 100–110 mm (3.9–4.3 in) – hatching
== Tissue distribution and secretion == Human and mouse PGLYRP2 is constitutively expressed in the adult and fetal liver, from where it is secreted into the blood. PGLYRP2 (NAMLAA) is present in human plasma at 100 to 200 μg/mL and at lower concentrations in saliva, milk, cerebrospinal fluid, and synovial fluid. PGLYRP2 is also expressed to a much lower level in the colon, lymph nodes, spleen, thymus, heart, and polymorphonuclear leukocyte granules. PGLYRP2 is differentially expressed in the developing brain and this expression is influenced by the intestinal microbiome. Bacteria and cytokines induce low level of PGLYRP2 expression in the skin and gastrointestinal and oral epithelial cells, and also in intestinal intraepithelial T lymphocytes, dendritic cells, NK (natural killer) cells, and inflammatory macrophages. Some mammals, e.g. pigs, express multiple splice forms of PGLYRP2 with differential expression. Bacteria and cytokines induce expression of PGLYRP2 in epithelial cells through the p38 mitogen activated protein kinase (MAPK) and IRAK1 (interleukin-1 receptor-associated kinase 1) signaling pathways. Constitutive and induced expression of PGLYRP2 is controlled by different transcription factors whose binding sequences are located in different regions of the PGLYRP2 promoter. Constitutive expression of PGLYRP2 in hepatocytes is regulated by transcription factors c-Jun and ATF2 (activating transcription factor 2) through sequences in the proximal region of the promoter.
Macleod's reputation in Canada remained under the influence of Banting and Best's story for decades, so Macleod was not esteemed there. His contribution to science is now recognized by the broad public, even in Canada. The auditorium of the Toronto University Medical Research Centre was named in his honour, as was Diabetes UK's award for patients who survive for 70 years with diabetes. In 2012, he was inducted into the Canadian Medical Hall of Fame.
In December 2008, the 3d BCT deployed to Baghdad, Iraq and redeployed to Ft. Bragg in November 2009. In August 2009, 1st BCT deployed once again to Iraq and redeployed late July 2010. During the months of August and September 2009, 4th BCT deployed again to Afghanistan and returned in August 2010 having lost 38 soldiers. In May 2011 1–505 (Task Force 1 Panther) deployed to Afghanistan in support of Operation Enduring Freedom. Dispersed throughout the country, 1st battalion was attached to various Special Operations elements. 1st battalion redeployed to Fort Bragg, NC in February 2012 having lost two paratroopers. The 2d Brigade deployed to the Al Anbar Governorate in Iraq in May 2011, for the last time, as part of Operation New Dawn. Its mission was to advise, train and assist the Iraqi Armed Forces and Ministry of the Interior forces, as part of the withdrawal of United States Forces – Iraq. Elements of 2d Brigade were among the last US combat units to withdraw from Baghdad. The brigade suffered the loss of the last American service member in Iraq, SPC. David E. Hickman, on 14 November 2011. They were part of the long convoy of equipment and troops who exited Iraq into Kuwait as OIF came to an end.
=== Charges against UCC and UCIL employees === UCC chairman and CEO Warren Anderson was arrested and released on bail by the Madhya Pradesh Police in Bhopal on 7 December 1984. Anderson was taken to UCC's house after which he was released six hours later on $2,100 bail and flown out on a government plane. These actions were allegedly taken under the direction of then chief secretary of the state, who was possibly instructed from the chief minister's office, who himself flew out of Bhopal immediately. Later in 1987, the Indian government summoned Anderson, eight other executives and two company affiliates to appear in Indian court on homicide charges. In response, Union Carbide said the company is not under Indian jurisdiction. In May 1988, Indian businessman J. R. D. Tata wrote a confidential letter to the then Prime Minister, Rajiv Gandhi, conveying Henry Kissinger's concern about delay in reaching a settlement. At the time, Kissinger was an adviser to Union Carbide and other US corporations. Rajiv Gandhi indicated that he would consider Kissinger's advice. The opposition Bharatiya Janata Party alleged that Rajiv Gandhi protected Warren Anderson in a secret political deal with U.S. President Ronald Reagan, with Gandhi securing Reagan's pardon of Adil Shahryar in exchange. Dow was a named respondent in cases arising from Union Carbide's business in Bhopal.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.